Clinical Trials: Overview
Heart Failure Drugs: Inotropic Agents
Heart Failure II: Pathophysiology
Clinical Trials
Preclinical Development: Overview
Pharmacodynamics: Overview and Principles
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jun 5, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Andrea Rognoni1, Alessandro Lupi, Maurizio Lazzero
1Coronary Care Unit, Hospital Maggiore della Carità, Novara, Italy.
Levosimendan enhances heart function by increasing calcium sensitivity and opening potassium channels, improving myocardial performance without raising oxygen demand. This novel inodilator shows promise for various cardiac conditions beyond standard heart failure treatment.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: